Illumina, Inc. (ILMN) fair value analysis

Nasdaq · Updated 2026-09-07

Illumina, Inc. is a company that develops and manufactures DNA sequencing and genetic analysis systems used in research, clinical diagnostics, and other applications. The company operates globally with operations across multiple regions including North America, Europe, and Asia-Pacific.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, ILMN is trading at a 10–25% premium to estimated fair value.

ILMN currently ranks #98 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $198.16
Sector: Healthcare
12-month range: $102.26–$198.16

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: Moderate
Margin trend: Expanding
Revenue growth: Modest
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The top quarter of its range

What our data shows for ILMN

Our model validated 10 trailing price-to-earnings windows for ILMN, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $102.26–$198.16.
The 14-day relative strength index sits at a neutral 58.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for ILMN
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent ILMN news

TickrTrends' derived news-sentiment signal for ILMN is currently leaning positive, computed from recent coverage.

Illumina: Priced For Perfection It Hasn't Earned Yet (NASDAQ:ILMN) (seekingalpha.com, 2026-09-08)
TickrTrends take: Illumina trades at a premium valuation according to TickrTrends, which currently rates the stock as overvalued despite its position as a major player in healthcare diagnostics and sequencing. The headline suggests the market may be pricing in future growth or profitability that the company has not yet demonstrated, creating a gap between current expectations and actual results. Investors focused on valuation metrics should monitor whether ILMN can narrow this gap through operational improvements or revenue growth that justifies its current market price.
Illumina and Everpure to Join S&P 500 in September Rebalancing: What it Means for Investors (insidermonkey.com, 2026-09-07)
TickrTrends take: Illumina's inclusion in the S&P 500 is likely to bring increased institutional capital flows to the stock, which could apply upward pressure on its valuation metrics. Given TickrTrends' current assessment that ILMN is overvalued, investors focused on valuation should monitor whether the index rebalancing event amplifies this overvaluation or whether fundamental healthcare sector dynamics shift the company's valuation standing. The timing of entry for index funds during the September rebalancing period will be a key factor for value-conscious investors to track as demand for the stock potentially increases.
Illumina Inc (ILMN) Stock Up 3.9% but GF Value Says Overvalued -- GF Score: 71/100 (gurufocus.com, 2026-09-03)
TickrTrends take: Illumina's recent 3 percent stock price increase occurs within a context where TickrTrends' valuation analysis indicates the stock trades above intrinsic value levels. The company's GF Score of 71 out of 100 suggests moderate quality fundamentals, though this assessment does not override the overvaluation determination for investors focused on valuation metrics. For those tracking price relative to underlying business value in the healthcare sector, the divergence between near-term price momentum and longer-term valuation positioning warrants attention.

What people are saying

Follow the ILMN conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for ILMN shifted this week with the DCF cross-check band moving from an overvalued assessment to none, while the 50/200-day trend state transitioned from uptrend to mixed. The current valuation verdict remains overvalued. These changes suggest reduced confidence in certain valuation metrics alongside a loss of directional momentum in the stock's shorter and longer-term price trends.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is ILMN stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), ILMN is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is ILMN's TickrTrends verdict?

ILMN's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does ILMN compare to other Healthcare stocks?

ILMN ranks #98 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is ILMN overbought or oversold?

ILMN's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

ILMN vs BMY · ILMN vs CAH · ILMN vs CNC · ILMN vs CRL · ILMN vs DGX